Lipid-Lowering Agents - Netherlands

Netherlands

The Netherlands is projected to witness a significant revenue growth in the Lipid-Lowering Agents market.
In 2024, the revenue is expected to reach €53.82m.
Furthermore, a steady annual growth rate (CAGR 2024-2029) of 0.11% is anticipated, resulting in a market volume of €54.11m by 2029.
When compared globally, United States is expected to generate the highest revenue in the Lipid-Lowering Agents market, with a projected revenue of €4,137.00m in 2024.
The Netherlands has seen a significant increase in the use of lipid-lowering agents, indicating a growing awareness and focus on cardiovascular health in the country.

Key regions: Europe, Brazil, France, Australia, Germany

Mercado

Región

Comparación de regiones

Moneda

Analyst Opinion

The demand for Lipid-Lowering Agents in the Netherlands has been on the rise in recent years.

Customer preferences: The Dutch population is becoming increasingly health-conscious, leading to a growing demand for preventative healthcare products. Lipid-Lowering Agents are popular among individuals with high cholesterol levels or those at risk of developing cardiovascular diseases. Additionally, the aging population in the Netherlands is also contributing to the growth of this market, as older individuals are more likely to require medication to manage their health.

Trends in the market: The market for Lipid-Lowering Agents in the Netherlands is characterized by intense competition among a few key players. Statins are the most commonly prescribed Lipid-Lowering Agents, accounting for a significant share of the market. However, there is a growing trend towards the use of alternative therapies, such as PCSK9 inhibitors and bile acid sequestrants, which are gaining popularity due to their effectiveness in reducing LDL cholesterol levels.

Local special circumstances: The Dutch healthcare system is heavily regulated, with strict rules and guidelines governing the prescription and distribution of medication. This has led to a highly centralized market, with a few large pharmaceutical companies dominating the industry. Additionally, the Dutch government has implemented cost-containment measures in recent years, leading to increased pressure on pharmaceutical companies to reduce prices and improve efficiency.

Underlying macroeconomic factors: The Dutch economy has been growing steadily in recent years, with low unemployment rates and a stable political environment. This has led to increased consumer confidence and spending, contributing to the growth of the healthcare industry as a whole. Additionally, the Netherlands has a strong tradition of innovation and research, with a highly educated workforce and a supportive business environment. This has led to the development of new and innovative Lipid-Lowering Agents, driving growth in the market.

Methodology

Data coverage:

Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.

Modeling approach / Market size:

Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.

Forecasts:

In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.

Additional notes:

Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.